You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDeferasirox
Accession NumberDB01609
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDeferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.
Structure
Thumb
Synonyms
Deferasiroxum
Exjade
ICL 670
ICL 670a
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ExjadeFilm-coated tablet90 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
Exjadetablet for suspension250 mgoralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada
ExjadeDispersible tablet250 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet360 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
Exjadetablet, for suspension125 mg/1oralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs
ExjadeFilm-coated tablet180 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeDispersible tablet250 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet90 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
Exjadetablet for suspension500 mgoralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada
Exjadetablet, for suspension250 mg/1oralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs
ExjadeDispersible tablet500 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeDispersible tablet125 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet180 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeDispersible tablet500 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet90 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
Exjadetablet, for suspension500 mg/1oralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs
ExjadeDispersible tablet500 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeDispersible tablet125 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet360 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
Exjadetablet for suspension125 mgoralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada
ExjadeDispersible tablet500 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet180 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeDispersible tablet125 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeDispersible tablet250 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeFilm-coated tablet360 mgOral useNovartis Europharm Limited2006-08-28Not applicableEu
Jadenutablet360 mgoralNovartis Pharmaceuticals Canada Inc2016-03-24Not applicableCanada
Jadenutablet, film coated180 mg/1oralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs
Jadenutablet, film coated360 mg/1oralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs
Jadenutablet90 mgoralNovartis Pharmaceuticals Canada Inc2016-03-24Not applicableCanada
Jadenutablet180 mgoralNovartis Pharmaceuticals Canada Inc2016-03-24Not applicableCanada
Jadenutablet, film coated90 mg/1oralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV8G4MOF2V9
CAS number201530-41-8
WeightAverage: 373.3615
Monoisotopic: 373.106255983
Chemical FormulaC21H15N3O4
InChI KeyInChIKey=BOFQWVMAQOTZIW-UHFFFAOYSA-N
InChI
InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
IUPAC Name
4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
SMILES
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenyl-1,3,4-triazoles. These are organic compounds containing a 1,3,4-triazole substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTriazoles
Direct ParentPhenyl-1,3,4-triazoles
Alternative Parents
Substituents
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
PharmacodynamicsDeferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Mechanism of actionTwo molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.
Related Articles
AbsorptionThe absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
Volume of distribution
  • 14.37 ± 2.69 L
Protein bindingDeferasirox is highly (~99%) protein bound almost exclusively to serum albumin.
Metabolism

Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.

Route of eliminationDeferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).
Half lifeThe mean elimination half-life ranged from 8 to 16 hours following oral administration.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.993
Blood Brain Barrier+0.8508
Caco-2 permeable+0.5089
P-glycoprotein substrateNon-substrate0.7808
P-glycoprotein inhibitor INon-inhibitor0.894
P-glycoprotein inhibitor IINon-inhibitor0.8431
Renal organic cation transporterNon-inhibitor0.8708
CYP450 2C9 substrateNon-substrate0.7212
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateNon-substrate0.6466
CYP450 1A2 substrateNon-inhibitor0.5802
CYP450 2C9 inhibitorNon-inhibitor0.7105
CYP450 2D6 inhibitorNon-inhibitor0.8221
CYP450 2C19 inhibitorNon-inhibitor0.5918
CYP450 3A4 inhibitorNon-inhibitor0.8179
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5717
Ames testNon AMES toxic0.6607
CarcinogenicityNon-carcinogens0.8519
BiodegradationNot ready biodegradable0.9524
Rat acute toxicity2.1119 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9684
hERG inhibition (predictor II)Non-inhibitor0.9072
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Dispersible tabletOral use125 mg
Dispersible tabletOral use250 mg
Dispersible tabletOral use500 mg
Film-coated tabletOral use180 mg
Film-coated tabletOral use360 mg
Film-coated tabletOral use90 mg
Tablet for suspensionoral125 mg
Tablet for suspensionoral250 mg
Tablet for suspensionoral500 mg
Tablet, for suspensionoral125 mg/1
Tablet, for suspensionoral250 mg/1
Tablet, for suspensionoral500 mg/1
Tabletoral180 mg
Tabletoral360 mg
Tabletoral90 mg
Tablet, film coatedoral180 mg/1
Tablet, film coatedoral360 mg/1
Tablet, film coatedoral90 mg/1
Prices
Unit descriptionCostUnit
Exjade 500 mg tablet78.61USD tablet
Exjade 250 mg tablet39.3USD tablet
Exjade 125 mg tablet19.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2255951 No2006-10-102017-06-24Canada
US6465504 No1999-04-052019-04-05Us
US6596750 No1997-06-242017-06-24Us
US9283209 No2014-11-212034-11-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point116-117 °CNot Available
water solubility0.038 mg/mL at 37 °CYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.52HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0343 mg/mLALOGPS
logP4.01ALOGPS
logP4.74ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.55ChemAxon
pKa (Strongest Basic)0.19ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area108.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity125.32 m3·mol-1ChemAxon
Polarizability38.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Rajendra Suryabhan Patil, Kishore Charugundla, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson, “SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF.” U.S. Patent US20110171138, issued July 14, 2011.

US20110171138
General ReferencesNot Available
External Links
ATC CodesV03AC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Deferasirox.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Deferasirox.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Deferasirox.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Deferasirox.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Deferasirox.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Deferasirox.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Deferasirox.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Deferasirox.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Deferasirox.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Deferasirox.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Deferasirox.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Deferasirox.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Deferasirox.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Deferasirox.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Deferasirox.
Alendronic acidThe risk or severity of adverse effects can be increased when Alendronic acid is combined with Deferasirox.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Deferasirox.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Deferasirox.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Deferasirox.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Deferasirox.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Deferasirox.
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Deferasirox.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Deferasirox.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Deferasirox.
Aluminum hydroxideThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Deferasirox.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Deferasirox.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Deferasirox.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Deferasirox.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Deferasirox.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Deferasirox.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Deferasirox.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Deferasirox.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Deferasirox.
AnagrelideThe serum concentration of Anagrelide can be increased when it is combined with Deferasirox.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Deferasirox.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Deferasirox.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Deferasirox.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Deferasirox.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Deferasirox.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Deferasirox.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Deferasirox.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Deferasirox.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Deferasirox.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Deferasirox.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Deferasirox.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Deferasirox.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Deferasirox.
ASA404The serum concentration of ASA404 can be increased when it is combined with Deferasirox.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Deferasirox.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Deferasirox.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Deferasirox.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.
AV650The serum concentration of AV650 can be increased when it is combined with Deferasirox.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Deferasirox.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Deferasirox.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Deferasirox.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Deferasirox.
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Deferasirox.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Deferasirox.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Deferasirox.
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Deferasirox.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Deferasirox.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Deferasirox.
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Deferasirox.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Deferasirox.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Deferasirox.
BeraprostThe serum concentration of Beraprost can be increased when it is combined with Deferasirox.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Deferasirox.
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Deferasirox.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Deferasirox.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Deferasirox.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Deferasirox.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Deferasirox.
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Deferasirox.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Deferasirox.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Deferasirox.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Deferasirox.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Deferasirox.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Deferasirox.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deferasirox.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Deferasirox.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Deferasirox.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Deferasirox.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Deferasirox.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Deferasirox.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Deferasirox.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Deferasirox.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Deferasirox.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Deferasirox.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Deferasirox.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Deferasirox.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Deferasirox.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Deferasirox.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Deferasirox.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Deferasirox.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Deferasirox.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Deferasirox.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Deferasirox.
CarmustineThe serum concentration of Carmustine can be increased when it is combined with Deferasirox.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Deferasirox.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Deferasirox.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Deferasirox.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Deferasirox.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Deferasirox.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Deferasirox.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Deferasirox.
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Deferasirox.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Deferasirox.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Deferasirox.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Deferasirox.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Deferasirox.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Deferasirox.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Deferasirox.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Deferasirox.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Deferasirox.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Deferasirox.
CholestyramineThe serum concentration of Deferasirox can be decreased when it is combined with Cholestyramine.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Deferasirox.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Deferasirox.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Deferasirox.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Deferasirox.
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Deferasirox.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Deferasirox.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deferasirox.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Deferasirox.
ClenbuterolThe serum concentration of Clenbuterol can be increased when it is combined with Deferasirox.
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Deferasirox.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Deferasirox.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Deferasirox.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Deferasirox.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox.
ClodronateThe risk or severity of adverse effects can be increased when Clodronate is combined with Deferasirox.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Deferasirox.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Deferasirox.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Deferasirox.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Deferasirox.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Deferasirox.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Deferasirox.
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Deferasirox.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Deferasirox.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Deferasirox.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Deferasirox.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Deferasirox.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Deferasirox.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Deferasirox.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Deferasirox.
ColesevelamThe serum concentration of Deferasirox can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Deferasirox can be decreased when it is combined with Colestipol.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Deferasirox.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Deferasirox.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Deferasirox.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Deferasirox.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Deferasirox.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Deferasirox.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Deferasirox.
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Deferasirox.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Deferasirox.
DacarbazineThe serum concentration of Dacarbazine can be increased when it is combined with Deferasirox.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Deferasirox.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Deferasirox.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Deferasirox.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Deferasirox.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Deferasirox.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Deferasirox.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Deferasirox.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Deferasirox.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Deferasirox.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Deferasirox.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Deferasirox.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Deferasirox.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Deferasirox.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Deferasirox.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Deferasirox.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Deferasirox.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Deferasirox.
DexfenfluramineThe serum concentration of Dexfenfluramine can be increased when it is combined with Deferasirox.
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Deferasirox.
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Deferasirox.
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Deferasirox.
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Deferasirox.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Deferasirox.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Deferasirox.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Deferasirox.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Deferasirox.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Deferasirox.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Deferasirox.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Deferasirox.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deferasirox.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Deferasirox.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Deferasirox.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Deferasirox.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Deferasirox.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Deferasirox.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Deferasirox.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Deferasirox.
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Deferasirox.
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Deferasirox.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Deferasirox.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Deferasirox.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Deferasirox.
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Deferasirox.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Deferasirox.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Deferasirox.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Deferasirox.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Deferasirox.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Deferasirox.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Deferasirox.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Deferasirox.
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Deferasirox.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Deferasirox.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Deferasirox.
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Deferasirox.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Deferasirox.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Deferasirox.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Deferasirox.
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Deferasirox.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Deferasirox.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Deferasirox.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deferasirox.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Deferasirox.
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Deferasirox.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Deferasirox.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Deferasirox.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Deferasirox.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Deferasirox.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Deferasirox.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Deferasirox.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Deferasirox.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Deferasirox.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Deferasirox.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Deferasirox.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Deferasirox.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Deferasirox.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Deferasirox.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Deferasirox.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Deferasirox.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Deferasirox.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Deferasirox.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Deferasirox.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Deferasirox.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Deferasirox.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deferasirox.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Deferasirox.
Etidronic acidThe risk or severity of adverse effects can be increased when Etidronic acid is combined with Deferasirox.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Deferasirox.
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Deferasirox.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Deferasirox.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Deferasirox.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Deferasirox.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Deferasirox.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Deferasirox.
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Deferasirox.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Deferasirox.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Deferasirox.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Deferasirox.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Deferasirox.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Deferasirox.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Deferasirox.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Deferasirox.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Deferasirox.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Deferasirox.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Deferasirox.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Deferasirox.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Deferasirox.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Deferasirox.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Deferasirox.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Deferasirox.
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Deferasirox.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Deferasirox.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Deferasirox.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Deferasirox.
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Deferasirox.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Deferasirox.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Deferasirox.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Deferasirox.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Deferasirox.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Deferasirox.
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Deferasirox.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Deferasirox.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Deferasirox.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Deferasirox.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Deferasirox.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Deferasirox.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Deferasirox.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Deferasirox.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Deferasirox.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Deferasirox.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Deferasirox.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Deferasirox.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Deferasirox.
FluvoxamineThe serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Deferasirox.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Deferasirox.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Deferasirox.
FosphenytoinThe serum concentration of Deferasirox can be decreased when it is combined with Fosphenytoin.
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Deferasirox.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Deferasirox.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Deferasirox.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Deferasirox.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Deferasirox.
GenisteinThe serum concentration of Genistein can be increased when it is combined with Deferasirox.
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Deferasirox.
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Deferasirox.
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Deferasirox.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Deferasirox.
GuanabenzThe serum concentration of Guanabenz can be increased when it is combined with Deferasirox.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Deferasirox.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Deferasirox.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Deferasirox.
HesperetinThe serum concentration of Hesperetin can be increased when it is combined with Deferasirox.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Deferasirox.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Deferasirox.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Deferasirox.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Deferasirox.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Deferasirox.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Deferasirox.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Deferasirox.
IbandronateThe risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Deferasirox.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Deferasirox.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Deferasirox.
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Deferasirox.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Deferasirox.
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Deferasirox.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Deferasirox.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Deferasirox.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Deferasirox.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Deferasirox.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Deferasirox.
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Deferasirox.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Deferasirox.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Deferasirox.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Deferasirox.
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Deferasirox.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Deferasirox.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Deferasirox.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Deferasirox.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Deferasirox.
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Deferasirox.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Deferasirox.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Deferasirox.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Deferasirox.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Deferasirox.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Deferasirox.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Deferasirox.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Deferasirox.
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Deferasirox.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Deferasirox.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Deferasirox.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Deferasirox.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Deferasirox.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Deferasirox.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Deferasirox.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Deferasirox.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Deferasirox.
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Deferasirox.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Deferasirox.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Deferasirox.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Deferasirox.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Deferasirox.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Deferasirox.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Deferasirox.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Deferasirox.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Deferasirox.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Deferasirox.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Deferasirox.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Deferasirox.
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Deferasirox.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Deferasirox.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Deferasirox.
LomefloxacinThe serum concentration of Lomefloxacin can be increased when it is combined with Deferasirox.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Deferasirox.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Deferasirox.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Deferasirox.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Deferasirox.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Deferasirox.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deferasirox.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Deferasirox.
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Deferasirox.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Deferasirox.
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Deferasirox.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Deferasirox.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Deferasirox.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deferasirox.
MalathionThe serum concentration of Malathion can be increased when it is combined with Deferasirox.
MaprotilineThe serum concentration of Maprotiline can be increased when it is combined with Deferasirox.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Deferasirox.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Deferasirox.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Deferasirox.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Deferasirox.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Deferasirox.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Deferasirox.
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Deferasirox.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Deferasirox.
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Deferasirox.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Deferasirox.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Deferasirox.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deferasirox.
MenadioneThe serum concentration of Menadione can be increased when it is combined with Deferasirox.
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Deferasirox.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Deferasirox.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Deferasirox.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Deferasirox.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Deferasirox.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Deferasirox.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Deferasirox.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Deferasirox.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deferasirox.
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Deferasirox.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Deferasirox.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Deferasirox.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Deferasirox.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Deferasirox.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Deferasirox.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Deferasirox.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Deferasirox.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Deferasirox.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Deferasirox.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Deferasirox.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Deferasirox.
muraglitazarThe serum concentration of muraglitazar can be increased when it is combined with Deferasirox.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Deferasirox.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Deferasirox.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.
NabumetoneThe serum concentration of Nabumetone can be increased when it is combined with Deferasirox.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deferasirox.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Deferasirox.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Deferasirox.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Deferasirox.
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Deferasirox.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Deferasirox.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Deferasirox.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Deferasirox.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Deferasirox.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Deferasirox.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Deferasirox.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Deferasirox.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Deferasirox.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Deferasirox.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deferasirox.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Deferasirox.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Deferasirox.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deferasirox.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Deferasirox.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Deferasirox.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Deferasirox.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.
Nitric OxideThe serum concentration of Nitric Oxide can be increased when it is combined with Deferasirox.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Deferasirox.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Deferasirox.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Deferasirox.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Deferasirox.
OlodaterolThe serum concentration of Olodaterol can be increased when it is combined with Deferasirox.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Deferasirox.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Deferasirox.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Deferasirox.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Deferasirox.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Deferasirox.
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Deferasirox.
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Deferasirox.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Deferasirox.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Deferasirox.
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Deferasirox.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Deferasirox.
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Deferasirox.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Deferasirox.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Deferasirox.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Deferasirox.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deferasirox.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Deferasirox.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Deferasirox.
PamidronateThe risk or severity of adverse effects can be increased when Pamidronate is combined with Deferasirox.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Deferasirox.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Deferasirox.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Deferasirox.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Deferasirox.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Deferasirox.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Deferasirox.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Deferasirox.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Deferasirox.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Deferasirox.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deferasirox.
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Deferasirox.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Deferasirox.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Deferasirox.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Deferasirox.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Deferasirox.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Deferasirox.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Deferasirox.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Deferasirox.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Deferasirox.
PhenobarbitalThe serum concentration of Deferasirox can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Deferasirox.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Deferasirox.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Deferasirox.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Deferasirox.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Deferasirox.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Deferasirox.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Deferasirox.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Deferasirox.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Deferasirox.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Deferasirox.
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Deferasirox.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Deferasirox.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deferasirox.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Deferasirox.
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Deferasirox.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Deferasirox.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Deferasirox.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Deferasirox.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Deferasirox.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Deferasirox.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Deferasirox.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Deferasirox.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Deferasirox.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Deferasirox.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Deferasirox.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Deferasirox.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Deferasirox.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Deferasirox.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Deferasirox.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Deferasirox.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Deferasirox.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Deferasirox.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Deferasirox.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Deferasirox.
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Deferasirox.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Deferasirox.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Deferasirox.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Deferasirox.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Deferasirox.
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Deferasirox.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Deferasirox.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Deferasirox.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Deferasirox.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Deferasirox.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Deferasirox.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Deferasirox.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Deferasirox.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Deferasirox.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Deferasirox.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Deferasirox.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Deferasirox.
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Deferasirox.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Deferasirox.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Deferasirox.
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Deferasirox.
ResveratrolThe serum concentration of Resveratrol can be increased when it is combined with Deferasirox.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Deferasirox.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Deferasirox.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Deferasirox.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Deferasirox.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Deferasirox.
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Deferasirox.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Deferasirox.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Deferasirox.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Deferasirox.
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Deferasirox.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Deferasirox.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Deferasirox.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Deferasirox.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Deferasirox.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Deferasirox.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Deferasirox.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Deferasirox.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Deferasirox.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Deferasirox.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Deferasirox.
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Deferasirox.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Deferasirox.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Deferasirox.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Deferasirox.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Deferasirox.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Deferasirox.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Deferasirox.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Deferasirox.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Deferasirox.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Deferasirox.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Deferasirox.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Deferasirox.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Deferasirox.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Deferasirox.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Deferasirox.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Deferasirox.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Deferasirox.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Deferasirox.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Deferasirox.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Deferasirox.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Deferasirox.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Deferasirox.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Deferasirox.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Deferasirox.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Deferasirox.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Deferasirox.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Deferasirox.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Deferasirox.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Deferasirox.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Deferasirox.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Deferasirox.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Deferasirox.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Deferasirox.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deferasirox.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Deferasirox.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Deferasirox.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Deferasirox.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Deferasirox.
TacrineThe serum concentration of Tacrine can be increased when it is combined with Deferasirox.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Deferasirox.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Deferasirox.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Deferasirox.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Deferasirox.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Deferasirox.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Deferasirox.
TazaroteneThe serum concentration of Tazarotene can be increased when it is combined with Deferasirox.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Technetium Tc-99m Medronate is combined with Deferasirox.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Deferasirox.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Deferasirox.
TemafloxacinThe serum concentration of Temafloxacin can be increased when it is combined with Deferasirox.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Deferasirox.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Deferasirox.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Deferasirox.
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Deferasirox.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Deferasirox.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Deferasirox.
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Deferasirox.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Deferasirox.
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Deferasirox.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Deferasirox.
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Deferasirox.
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Deferasirox.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Deferasirox.
ThiabendazoleThe serum concentration of Thiabendazole can be increased when it is combined with Deferasirox.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Deferasirox.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Deferasirox.
ThiothixeneThe serum concentration of Thiothixene can be increased when it is combined with Deferasirox.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Deferasirox.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Deferasirox.
TiludronateThe risk or severity of adverse effects can be increased when Tiludronate is combined with Deferasirox.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Deferasirox.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Deferasirox.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Deferasirox.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Deferasirox.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Deferasirox.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Deferasirox.
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Deferasirox.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deferasirox.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deferasirox.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Deferasirox.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Deferasirox.
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Deferasirox.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Deferasirox.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Deferasirox.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Deferasirox.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Deferasirox.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Deferasirox.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Deferasirox.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Deferasirox.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Deferasirox.
TriamtereneThe serum concentration of Triamterene can be increased when it is combined with Deferasirox.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Deferasirox.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Deferasirox.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Deferasirox.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Deferasirox.
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Deferasirox.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Deferasirox.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Deferasirox.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Deferasirox.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Deferasirox.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Deferasirox.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Deferasirox.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Deferasirox.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Deferasirox.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Deferasirox.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Deferasirox.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Deferasirox.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Deferasirox.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Deferasirox.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Deferasirox.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Deferasirox.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Deferasirox.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Deferasirox.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Deferasirox.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Deferasirox.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Deferasirox.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Deferasirox.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Deferasirox.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Deferasirox.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Deferasirox.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Deferasirox.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Deferasirox.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Deferasirox.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deferasirox.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Deferasirox.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Deferasirox.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Deferasirox.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Deferasirox.
Zoledronic acidThe risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox.
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Deferasirox.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Deferasirox.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Deferasirox.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Deferasirox.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Deferasirox.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Deferasirox.
Food Interactions
  • Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.
  • Food causes inconsistent increases in the bioavailability of this product.
  • Tablets should be completely dispersed in water, orange juice or apple juice and the resulting suspension should be ingested immediately (after swallowing the suspension, any residue should be resuspended in a small volume of liquid and swallowed).
  • Tablets should be taken on an empty stomach at least 30 minutes before a meal, preferably at the same time everyday.

Targets

1. Iron
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
chelator
References
  1. Wang T, Gao C, Chen BA: [Deferasirox--a new oral iron chelator--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1359-64. [PubMed:21129294 ]
  2. Ibrahim AS, Spellberg B, Edwards J Jr: Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008 Dec;21(6):620-5. doi: 10.1097/QCO.0b013e3283165fd1. [PubMed:18978530 ]
  3. Devanur LD, Evans RW, Evans PJ, Hider RC: Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy. Biochem J. 2008 Jan 15;409(2):439-47. [PubMed:17919118 ]
  4. Lebitasy M, Ampe E, Hecq JD, Karmani L, Nick H, Galanti L: Ability of deferasirox to bind iron during measurement of iron. Clin Chem Lab Med. 2010 Mar;48(3):427-9. doi: 10.1515/CCLM.2010.080. [PubMed:20170398 ]
  5. Yang LP, Keam SJ, Keating GM: Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. [PubMed:17927285 ]
  6. Choudhry VP, Naithani R: Current status of iron overload and chelation with deferasirox. Indian J Pediatr. 2007 Aug;74(8):759-64. [PubMed:17785900 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Skerjanec A, Wang J, Maren K, Rojkjaer L: Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):205-13. doi: 10.1177/0091270009340418. Epub 2009 Nov 25. [PubMed:19940232 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 13:21 / Updated on September 28, 2016 03:02